Last reviewed · How we verify
Trivalent ganglioside vaccine — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Trivalent ganglioside vaccine (Trivalent ganglioside vaccine) — MabVax Therapeutics, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Trivalent ganglioside vaccine TARGET | Trivalent ganglioside vaccine | MabVax Therapeutics, Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Trivalent ganglioside vaccine CI watch — RSS
- Trivalent ganglioside vaccine CI watch — Atom
- Trivalent ganglioside vaccine CI watch — JSON
- Trivalent ganglioside vaccine alone — RSS
Cite this brief
Drug Landscape (2026). Trivalent ganglioside vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/trivalent-ganglioside-vaccine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab